Findings

What do systematic reviews say?

34 questions · 34 findings · 7 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 2.9%GRADE not reported 3 · 8.8%Very low 0 · 0%Low 12 · 35.3%Moderate 5 · 14.7%High 13 · 38.2%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Creatine vs placebo · UPDRS motor score
  Creatine for Parkinson's disease 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 194 participants
  Low
Direct match · question page
- Oral creatine vs placebo · Change in total muscle strength (total muscle strength)
  Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Low
Direct match · question page
- Oral creatine vs placebo · Time from beginning of treatment until death or full‐time ventilation
  Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Moderate
Direct match · question page
- Oral creatine vs placebo · Change in disability score
  Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Moderate
Direct match · question page
- Oral creatine vs placebo · Acquiring the ability to stand or walk
  Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Creatine vs placebo

UPDRS III UPDRS scale (motor score). Scale from: 0 to 56. · people with Parkinson's disease

1 finding from 1 review

Creatine for Parkinson's disease 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 194 participants
Low

Creatine vs placebo

UPDRS ADL score · people with Parkinson's disease

1 finding from 1 review

Creatine for Parkinson's disease 2014 · Cochrane Headline outcomes only
0.37
2 studies · 194 participants
Low

Oral creatine vs placebo

Change in disability score · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Oral creatine vs placebo

Muscle strength · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Low

Oral creatine vs placebo

Acquiring the ability to stand or walk · children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral creatine vs placebo

Change in quality of life · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Oral creatine vs placebo

Change in pulmonary function · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Oral creatine vs placebo

Time from beginning of treatment until death or full‐time ventilation · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Oral creatine vs placebo

Adverse events related to treatment · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Intervention not reported

Creatine phosphate 1g/day · patients with heart failure

1 finding from 1 review

Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 13 participants
Low

Intervention not reported

Creatine 20g/day for 6 weeks · patients with heart failure

1 finding from 1 review

Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 13 participants
Low

Intervention not reported

Creatine 20g/day for 10 days · patients with heart failure

1 finding from 1 review

Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Low

Intervention not reported

Myopathy: proportion with changed serum creatine kinase levels (>10x ULN) ‐ at all time points · children with familial hypercholesterolemia

1 finding from 1 review

Statins for children with familial hypercholesterolemia 2019 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 6694 participants
Low

Intervention not reported

hour Plasma Creatine Phosphokinase · patients with acute coronary syndrome

1 finding from 1 review

Hyperbaric oxygen therapy for acute coronary syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 84 participants
Moderate

Intervention not reported

hour Plasma Creatine Phosphate · patients with acute coronary syndrome

1 finding from 1 review

Hyperbaric oxygen therapy for acute coronary syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 72 participants
Moderate

Intervention not reported

Maximum Plasma Creatine Phosphate · patients with acute coronary syndrome

1 finding from 1 review

Hyperbaric oxygen therapy for acute coronary syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 184 participants
High

Intervention not reported

Maximum voluntary contraction in dystrophinopathies % · patients with muscular dystrophies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 121 participants
High

Intervention not reported

Adverse events in glycogen storage disease type V · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 28 participants
GRADE not reported

Intervention not reported

Aggregate functional performance time (AFPT), intention‐to‐treat analysis % · patients with idiopathic inflammatory myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
High

Intervention not reported

AFPT, valid compliant completer analysis % · patients with idiopathic inflammatory myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 29 participants
High